We are live on ! Find out more
KIA

Kopp Investment Advisors Portfolio holdings

AUM $54.4M
1-Year Est. Return 14.33%
This Fund
S&P 500
This Quarter Est. Return
+2.4%
1 Year Est. Return
+14.33%
3 Year Est. Return
+109.21%
5 Year Est. Return
+340.72%
10 Year Est. Return
AUM
$202M
AUM Growth
-$15.5M
Cap. Flow
-$7.15M
Cap. Flow %
-3.54%
Top 10 Hldgs %
56.78%
Holding
73
New
3
Increased
15
Reduced
45
Closed
5

Sector Composition

Rank Sector Weight
1 Technology 38.6%
2 Healthcare 34.47%
3 Miscellaneous 13.94%
4 Consumer Staples 4.56%
5 Financials 1.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VTSS
1
DELISTED
VITESSE SEMICONDUCTOR CORPORATION COMMON STOCK
VTSS
$20.2M 10.01%
5,618,041
+21,705
+0.4% +$70.5K
EMKR
2
DELISTED
Emcore Corp
EMKR
$17.4M 8.6%
305,536
+850
+0.3% +$37.1K
FNSR
3
DELISTED
Finisar Corp
FNSR
$16.8M 8.32%
1,011,146
-3,445
-0.3% -$66.6K
OCLR
4
DELISTED
Oclaro Inc.
OCLR
$14.2M 7.02%
9,919,560
-46,820
-0.5% -$85.9K
SRGA
5
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$8.66M 4.29%
60,425
-2,539
-4% -$368K
NEO icon
6
NeoGenomics
NEO
$2.39B
$8.39M 4.15%
1,611,132
+1,102,215
+217% +$5.66M
TLGT
7
DELISTED
Teligent, Inc
TLGT
$7.36M 3.64%
78,986
+45,967
+139% +$2.94M
SCON
8
DELISTED
Superconductor Technologies Inc.
SCON
$7.35M 3.64%
1,745
+1
+0.1% +$4.27K
STKL
9
DELISTED
SunOpta
STKL
$7.21M 3.57%
597,282
-86,175
-13% -$1.14M
ARRY
10
DELISTED
Array Biopharma Inc
ARRY
$7.16M 3.54%
2,005,410
-6,490
-0.3% -$25.6K
SUPN icon
11
Supernus Pharmaceuticals
SUPN
$2.57B
$6.27M 3.1%
721,065
+56,595
+9% +$511K
PTX
12
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$6.1M 3.02%
79,466
+15,991
+25% +$1.26M
AKRX
13
DELISTED
Akorn Inc
AKRX
$5.1M 2.52%
140,693
-147,220
-51% -$5.28M
OMCL icon
14
Omnicell
OMCL
$1.52B
$4.43M 2.19%
161,958
-5,195
-3% -$142K
SWKS icon
15
Skyworks Solutions
SWKS
$10.1B
$3.97M 1.96%
68,334
-5,900
-8% -$315K
ENZ
16
DELISTED
Enzo Biochem, Inc.
ENZ
$3.4M 1.68%
659,620
+187,335
+40% +$999K
IDTI
17
DELISTED
Integrated Device Technology I
IDTI
$3.28M 1.62%
205,575
-2,425
-1% -$37.7K
ALU
18
DELISTED
Alcatel-Lucent
ALU
$3.22M 1.59%
1,062,521
-529,275
-33% -$1.8M
ATRC icon
19
AtriCure
ATRC
$2.51B
$3.06M 1.51%
207,655
+47,365
+30% +$754K
EXTR icon
20
Extreme Networks
EXTR
$3.03B
$3.01M 1.49%
627,682
-5,140
-0.8% -$25K
RKUS
21
DELISTED
RUCKUS WIRELESS INC COM STK (DE)
RKUS
$2.77M 1.37%
206,948
-1,970
-0.9% -$25.7K
KFX
22
DELISTED
KOFAX LIMITED COM STK
KFX
$2.51M 1.24%
324,418
-81,745
-20% -$629K
ANGO icon
23
AngioDynamics
ANGO
$652M
$2.19M 1.08%
159,288
-28,380
-15% -$405K
PODD icon
24
Insulet
PODD
$9.95B
$2.06M 1.02%
56,030
-650
-1% -$23.7K
TQNT
25
DELISTED
TRIQUINT SEMICONDUCTOR INC
TQNT
$1.66M 0.82%
87,194
-21,258
-20% -$395K

Similar funds

Kopp Investment Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Kopp Investment Advisors held 73 positions worth $202M, down 7.1% from $218M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Kopp Investment Advisors withdrew a net $7.15M in Q3 2014, closing 5 positions and reducing 45 holdings. Its most notable exit was STAAR Surgical, an estimated $4.14M position sold in full.

By sector, the portfolio is most concentrated in Technology at 39% of assets, down from 40% a quarter earlier, followed by Healthcare and Miscellaneous.

Against the trend, Kopp Investment Advisors opened a new position in Aemetis worth $1.26M.

  • Kopp Investment Advisors's largest Q3 2014 buy was Aemetis: 145,205 shares worth $1.26M.
  • Kopp Investment Advisors added most to NeoGenomics in Q3 2014, an estimated $5.66M increase.
  • Kopp Investment Advisors's biggest Q3 2014 reduction was Akorn Inc, cutting an estimated $5.28M.
  • Kopp Investment Advisors fully exited STAAR Surgical in Q3 2014, selling an estimated $4.14M.
  • Kopp Investment Advisors's ten largest holdings make up 57% of its $202M portfolio in Q3 2014.
  • Kopp Investment Advisors opened 3 new positions and closed 5 in Q3 2014.
  • Kopp Investment Advisors's portfolio value fell 7.1% quarter-over-quarter to $202M.

Based on Kopp Investment Advisors's 13F filing for Q3 2014, filed 4 Nov 2014.